Trial Profile
An Observational Study of ORALAIR (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2019
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Stallergenes SA
- 25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 25 Jul 2017 Status changed from recruiting to completed.
- 26 Jul 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.